Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Japanese financial...

    Japanese financial group MUFG sells 2.10pc shares in Cipla

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-23T10:00:45+05:30  |  Updated On 23 Jan 2020 10:00 AM IST
    Japanese financial group MUFG sells 2.10pc shares in Cipla

    "MUFG has sold an indirect interest in Cipla Ltd on account of sale of the following entities: First State Investment Management (UK) Ltd, First Sentier Investors (Australia) IM Ltd, First Sentier Investors (Australia) RE Ltd...on January 17, 2020," the homegrown pharma major said in a BSE filing.

    Japan: Japan's Mitsubishi UFJ Financial Group (MUFG) has sold 2.10 per cent shares in Cipla Ltd, according to a regulatory filing.

    "MUFG has sold an indirect interest in Cipla Ltd on account of sale of the following entities: First State Investment Management (UK) Ltd, First Sentier Investors (Australia) IM Ltd, First Sentier Investors (Australia) RE Ltd...on January 17, 2020," the homegrown pharma major said in a BSE filing.

    These entities directly hold shares in Cipla Ltd, it said.

    Also Read: No Relief: DOP Rejects Review Petition By CIPLA Challenging NPPA Price Fixation

    "The thresholds for disclosures...are met and currently, MUFG has an aggregated interest in Cipla Ltd of 3.46 per cent ordinary share capital, as on January 17, 2020, which is the date of sale. This is based on a total of 27,859, 785 shares held and a total of 806,227,596 voting rights on the issue," as per the filing.

    Prior to the sale, MUFG had 5.56 per cent shares in Cipla.

    Also Read: Cipla Patalganga Facility Gets EIR From USFDA

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok